Your Health, We Care
The TIVO-3 trial is a phase 3 clinical trial for patients with recurrent or refractory metastatic renal cell carcinoma. Patients treated with Tivozanib are more than five times more likely to experience long-term progression free survival than those treated with sorafenib.
Tivozanib, as a novel targeted anti-cancer drug, has shown positive prospects in the treatment of advanced renal cell carcinoma.
